Satellos Bioscience Inc. (MSCL.TO)
Satellos Bioscience Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $13.99, down 0.85% on the session, giving a market capitalisation of $291.4M. Its beta of 1.17 implies it has historically moved more than the broad market.
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
Satellos Bioscience Inc. is most often compared with the following Healthcare names: